

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-107. (cancelled).

108. (previously presented) A mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959.

109. (previously presented) An antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or antigen-binding fragment thereof.

110. (previously presented) The antibody of claim 109 which is a F(ab')₂ fragment.

111. (previously presented) The antibody of claim 109 which is a F(ab') fragment.

112. (withdrawn) The antibody of claim 109 which is conjugated to a therapeutic agent.

113. (withdrawn) The antibody of claim 112, wherein the therapeutic agent is a cytotoxin.

114. (withdrawn) The antibody of claim 113 wherein said cytotoxin is paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, or cyclophosphamide.

115. (withdrawn) The antibody of claim 109 comprising at least one modification in the Fc region.

116-122. (cancelled)

123. (previously presented) A pharmaceutical composition comprising (i) a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or antigen-binding fragment thereof; and (ii) a pharmaceutically acceptable carrier.

124. (cancelled)

125. (withdrawn) A method of treating or preventing an IgE-mediated allergic disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-

2960, and clone 1F2 having ATCC accession no. PTA-5959, or an antigen binding fragment thereof.

126. (withdrawn) The method of claim 125, wherein said IgE-mediated allergic disorder is asthma, allergic rhinitis, gastro-intestinal allergies, eosinophilia, conjunctivitis, or glomerular.

127. (withdrawn) The method of claim 125, wherein said patient is human.

128. (withdrawn) The method of claim 125, wherein said antibody is humanized.

129. (withdrawn) The method of claim 125, wherein the antibody is a $F(ab')_2$ fragment.

130. (withdrawn) The method of claim 125, wherein the antibody is a $F(ab')$ fragment.

131. (new) The pharmaceutical composition of claim 123, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.

132. (new) The pharmaceutical composition of claim 123, wherein said antibody is a humanized version, or antigen-binding fragment thereof.

133. (new) The pharmaceutical composition of claim 123, wherein said antibody is a $F(ab')_2$ fragment.

134. (new) The pharmaceutical composition of claim 123, wherein said antibody is a $F(ab')$ fragment.

135. (new) The antibody of claim 109, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.

136. (new) The antibody of claim 109, wherein said antibody is a humanized version,
or antigen-binding fragment thereof.